Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT)
Status:
Terminated
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase II Randomized, Open Label, Non-comparative Trial (Parallel Assignment and
Efficacy Study) for patients with HER-2 Negative Metastatic Breast Cancer Previously Treated
With chemotherapy in the Neo-Adjuvant or Adjuvant Setting.Patients will be randomized to
receive Ixabepilone either every three weeks, or weekly for three weeks followed by one week
off. Patients will be treated until consent withdrawal, intolerable toxicity or documented
disease progression